Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

43.54 -0.46 (-1.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

January 04, 2023

From Biogen Inc.

Via GlobeNewswire

The Latest Analyst Ratings for Ionis Pharmaceuticals ↗

December 21, 2022

Via Benzinga

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

December 13, 2022

Via Benzinga

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

4 Analysts Have This to Say About Ionis Pharmaceuticals ↗

November 10, 2022

Analysts have provided the following ratings for Ionis Pharmaceuticals (NASDAQ:IONS) within the last quarter:

Via Benzinga

Praxis Precision Outlines Upcoming Plans For Pediatric Epilepsy Programs ↗

September 07, 2022

Via Benzinga

Ionis Pharma Extends Breakout; Biotech Restates Guide Despite Quarterly Miss ↗

August 09, 2022

The guidance stayed intact despite a wide second-quarter flop.

Via Investor's Business Daily

Where Ionis Pharmaceuticals Stands With Analysts ↗

July 26, 2022

Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022 ↗

December 21, 2022

Via Benzinga

Phillips 66 To Rally 25%? Here Are 5 Other Price Target Changes For Thursday ↗

November 10, 2022

Via Benzinga

Ionis Regains Rights To Thrombosis Candidate From Bayer ↗

November 04, 2022

Via Benzinga

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

3 Biotech Stocks to Sell in October ↗

September 29, 2022

These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.

Via InvestorPlace

Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test ↗

September 29, 2022

Patients didn't show any improvements in a study meant to test multiple drugs.

Via Investor's Business Daily

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test ↗

September 23, 2022

Though successful in early testing, it wasn't enough to win a Phase 3 study.

Via Investor's Business Daily

AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med ↗

September 23, 2022

Via Benzinga

There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30% ↗

September 09, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

Analyst Ratings for Ionis Pharmaceuticals ↗

September 09, 2022

Over the past 3 months, 6 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗

September 07, 2022

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Ionis Pharmaceuticals: Q2 Earnings Insights ↗

August 09, 2022

Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday ↗

August 04, 2022

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.

Via Benzinga

Moderna, PayPal And Some Other Big Gainers From Wednesday ↗

August 04, 2022

U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 29, 2022

Good morning, trader! It's time to start off Friday with a breakdown of the biggest pre-market stock movers traders need to know about!

Via InvestorPlace

Recap Of Thursday's Biotech Catalysts - End of The Day Summary ↗

July 28, 2022

Via Benzinga

Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ↗

August 03, 2022

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.

Via Benzinga

Ionis Reveals Positive Results From Anti-Blood Clot Therapy In Hemodialysis ↗

July 28, 2022

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced positive topline results of the Phase 2b clinical trial of fesomersen in patients with end-stage renal disease (ESRD) on hemodialysis.

Via Benzinga

FDA Accepts Biogen's Submission For Neurodegenerative Disease Drug Under Priority Review ↗

July 26, 2022

The U.S. Food and Drug Administration (FDA) has accepted Biogen’s (NASDAQ: BIIB) New Drug Application (NDA) for its lead asset Tofersen for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis...

Via Benzinga

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate ↗

July 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.